Engineered in multi-ton synthesis facilities to comply with stringent global regulatory standards for purity, stability, and sequence fidelity.
Amyloid-beta (Aβ) peptides—most notably Aβ(1-42) and Aβ(1-40)—are central pathological hallmarks in Alzheimer’s Disease (AD) and cerebral amyloid angiopathy (CAA). Achieving high reproducibility in preclinical drug discovery demands unprecedented chemical purity and conformational control.
Aβ(1-42) is notorious for spontaneous oligomerization and β-sheet fibril assembly in physiological buffers. Thinheal applies proprietary TFA/HFIP monomerization protocols ensuring lot-to-lot kinetics reproducibility for high-throughput screening.
The hydrophobic C-terminus (residues 29-42: GAIIGLMVGGVVIA) causes intra-chain aggregation during SPPS. We utilize pseudoproline dipeptides, microwave-assisted coupling, and backbone protection to eliminate truncated impurities.
Residual trifluoroacetate (TFA) alters cellular toxicity assays and in vivo tolerability. Our factory offers validated salt-exchange protocols to supply peptides as pure Acetate, Hydrochloride, or physiological Sodium salts.
| Peptide Variant | Primary Target / Application | Purity (HPLC) | Salt Form | Lead Time |
|---|---|---|---|---|
| Amyloid β (1-42) Human | AD aggregation assays, fibrillization screening, in vivo animal models | ≥95% / ≥98% | TFA / Acetate / NaOH-treated | 1-2 Weeks (Stock Available) |
| Amyloid β (1-40) Human | Cerebral vascular amyloidosis, equilibrium affinity comparison | ≥95% / ≥98% | TFA / Acetate | 1-2 Weeks |
| HiLyte Fluor / FITC-Labeled Aβ | Fluorescence microscopy, receptor uptake tracking, live cell imaging | ≥95% | Acetate | 2-3 Weeks |
| Scrambled & Mutant Aβ (Arctic, Dutch) | Pathological controls, familial AD (FAD) kinetic baseline comparison | ≥95% | TFA / Acetate | 2-3 Weeks |
| Aβ (25-35) Fragment | Cost-effective neurotoxicity model, lipid peroxidation studies | ≥98% | TFA / Acetate | Immediate Delivery |
Hangzhou Thinheal Pharma-Tech leverages nearly two decades of executive experience in chemical synthesis and purification, delivering substantial cost and capacity advantages to Western biotechs and global enterprise buyers.
Our synthesis facilities located in the Heda Medicine Valley are directly integrated with raw amino acid manufacturing and specialized coupling reagents. This tight coupling yields a 30% to 50% reduction in production timelines and insulating enterprise partners from raw material volatility.
With an industrial capacity reaching the multi-ton level for peptide APIs, we easily shift from microgram exploratory batches to multi-kilogram cGMP regulatory campaigns. This scalability provides continuous regulatory dossiers (DMF, CMC) for pipeline progressions.
As regulatory approvals for monoclonal antibodies (e.g., Lecanemab, Donanemab) transform the neurodegenerative therapeutic market, procurement requirements for Amyloid peptides are shifting toward verified reproducibility and clinical compliance.
Pharmaceutical R&D pipelines require consistent reference standards for Thioflavin T (ThT) fluorescence and surface plasmon resonance (SPR) assays to evaluate small-molecule anti-aggregation candidates without background variability.
Next-generation AD vaccines focus on shorter N-terminal fragments (e.g., Aβ 1-6 or Aβ 1-15 conjugated to carrier proteins) to trigger humoral antibody responses without triggering meningoencephalitic T-cell toxicity.
With mass-spectrometry-based blood tests gaining clinical adoption, global IVD manufacturers procure ultra-pure isotope-labeled (13C, 15N) Aβ(1-40) and Aβ(1-42) to serve as internal standards for blood plasma quantification.
Clear, direct answers regarding custom peptide synthesis, storage protocols, and international supply continuity.
Explore our broader pipeline spanning metabolic modulators, neuro-active peptides, and custom cosmetic sequences available directly from our Hangzhou manufacturing base.
Thin
